公开(公告)号：US20180066231A1

公开(公告)日：2018-03-08

申请号：US15553868

申请日：2016-02-26

Applicant: ROHTO PHARMACEUTICAL CO., LTD.

Inventor： Yoshifumi IKEYAMA ,  Toru OKUBO ,  Hiroyuki NISHIDA ,  Tomohiro TSUDA ,  Eiko UNO ,  Masayo YUMOTO

IPC: C12N5/0775

CPC classification number: C12N5/0667 ,  C12N2500/05 ,  C12N2500/30 ,  C12N2501/10 ,  C12N2501/39

Abstract: The present invention aims to provide a mesenchymal stem cell culture medium suitable for culturing umbilical cord mesenchymal stem cells in particular, among the mesenchymal stem cells.The present invention is of a mesenchymal stem cell culture medium comprising at least 2 kinds of components selected from the group consisting of a PTEN inhibitor, a p53 inhibitor, a p38 inhibitor, an Wnt signal activator and a ROCK inhibitor as well as basal medium for culturing animal cells.

公开(公告)号：US20230277595A1

公开(公告)日：2023-09-07

申请号：US18016978

申请日：2022-02-09

Applicant: ROHTO PHARMACEUTICAL CO., LTD. ,  OSAKA UNIVERSITY

Inventor： Shunbun KITA ,  Emi HORITANI ,  Norikazu MAEDA ,  Iichiro SHIMOMURA ,  Hiroyuki NISHIDA

IPC: A61K35/28 ,  A61P3/10

CPC classification number: A61K35/28 ,  A61P3/10

Abstract: The present invention aims to provide a prophylactic and/or therapeutic agent for diabetes that is highly effective on diabetes developed as a side effect from immune checkpoint inhibitors and has a certain effect on many patients. The present invention is a therapeutic agent for diabetes comprising mesenchymal stem cells. The prophylactic and/or therapeutic agents for diabetes of the present invention are suitably used particularly for diabetes caused by immune checkpoint inhibitors and diabetes caused by anti-PD-1 antibody or anti-PD-L1 antibody.